GlassScriptPhysician profile
John L Kniaz
NPI 1659470110
$1,394.59
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $303 · 2021: $440 · 2022: $29.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.52 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.56 | 2019-2020 | |
| Janssen Biotech, INC. | $106.48 | 2019-2021 | |
| Allergan, INC. | $100.65 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $91.32 | 2019-2021 | |
| Braintree Laboratories, INC. | $71.21 | 2019-2021 | |
| Romark Laboratories, Lc | $58.76 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $37.83 | 2021 | |
| Ferring Pharmaceuticals INC. | $27.38 | 2020 | |
| Ucb, INC. | $25.25 | 2019 | |
| Evoke Pharma, INC. | $16.67 | 2021 | |
| Glaxosmithkline, LLC. | $15.69 | 2019 | |
| Shire North American Group INC | $13.43 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.24 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kniaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.